NEO
Price
$7.70
Change
+$0.44 (+6.06%)
Updated
May 2 closing price
Capitalization
2.01B
88 days until earnings call
VCYT
Price
$30.35
Change
+$0.64 (+2.15%)
Updated
May 2 closing price
Capitalization
1.66B
4 days until earnings call
Ad is loading...

NEO vs VCYT

Header iconNEO vs VCYT Comparison
Open Charts NEO vs VCYTBanner chart's image
NeoGenomics
Price$7.70
Change+$0.44 (+6.06%)
Volume$3.64M
Capitalization2.01B
Veracyte
Price$30.35
Change+$0.64 (+2.15%)
Volume$1.75M
Capitalization1.66B
NEO vs VCYT Comparison Chart
Loading...
NEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VCYT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NEO vs. VCYT commentary
May 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NEO is a Hold and VCYT is a Hold.

Ad is loading...
COMPARISON
Comparison
May 03, 2025
Stock price -- (NEO: $7.70 vs. VCYT: $30.35)
Brand notoriety: NEO and VCYT are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: NEO: 165% vs. VCYT: 169%
Market capitalization -- NEO: $2.01B vs. VCYT: $1.66B
NEO [@Medical Specialties] is valued at $2.01B. VCYT’s [@Medical Specialties] market capitalization is $1.66B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.41B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NEO’s FA Score shows that 0 FA rating(s) are green whileVCYT’s FA Score has 0 green FA rating(s).

  • NEO’s FA Score: 0 green, 5 red.
  • VCYT’s FA Score: 0 green, 5 red.
According to our system of comparison, VCYT is a better buy in the long-term than NEO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NEO’s TA Score shows that 4 TA indicator(s) are bullish while VCYT’s TA Score has 4 bullish TA indicator(s).

  • NEO’s TA Score: 4 bullish, 5 bearish.
  • VCYT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, VCYT is a better buy in the short-term than NEO.

Price Growth

NEO (@Medical Specialties) experienced а -25.02% price change this week, while VCYT (@Medical Specialties) price change was -5.83% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.26%. For the same industry, the average monthly price growth was -1.11%, and the average quarterly price growth was -1.23%.

Reported Earning Dates

NEO is expected to report earnings on Jul 30, 2025.

VCYT is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Medical Specialties (+1.26% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NEO($2.01B) has a higher market cap than VCYT($1.66B). VCYT YTD gains are higher at: -23.359 vs. NEO (-53.277). NEO has higher annual earnings (EBITDA): -17.61M vs. VCYT (-49.41M). NEO has more cash in the bank: 415M vs. VCYT (216M). VCYT has less debt than NEO: VCYT (12.6M) vs NEO (612M). NEO has higher revenues than VCYT: NEO (592M) vs VCYT (361M).
NEOVCYTNEO / VCYT
Capitalization2.01B1.66B121%
EBITDA-17.61M-49.41M36%
Gain YTD-53.277-23.359228%
P/E Ratio49.50N/A-
Revenue592M361M164%
Total Cash415M216M192%
Total Debt612M12.6M4,857%
FUNDAMENTALS RATINGS
NEO vs VCYT: Fundamental Ratings
NEO
VCYT
OUTLOOK RATING
1..100
1866
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
82
Overvalued
PROFIT vs RISK RATING
1..100
10086
SMR RATING
1..100
9187
PRICE GROWTH RATING
1..100
9459
P/E GROWTH RATING
1..100
10063
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NEO's Valuation (73) in the Medical Or Nursing Services industry is in the same range as VCYT (82) in the Biotechnology industry. This means that NEO’s stock grew similarly to VCYT’s over the last 12 months.

VCYT's Profit vs Risk Rating (86) in the Biotechnology industry is in the same range as NEO (100) in the Medical Or Nursing Services industry. This means that VCYT’s stock grew similarly to NEO’s over the last 12 months.

VCYT's SMR Rating (87) in the Biotechnology industry is in the same range as NEO (91) in the Medical Or Nursing Services industry. This means that VCYT’s stock grew similarly to NEO’s over the last 12 months.

VCYT's Price Growth Rating (59) in the Biotechnology industry is somewhat better than the same rating for NEO (94) in the Medical Or Nursing Services industry. This means that VCYT’s stock grew somewhat faster than NEO’s over the last 12 months.

VCYT's P/E Growth Rating (63) in the Biotechnology industry is somewhat better than the same rating for NEO (100) in the Medical Or Nursing Services industry. This means that VCYT’s stock grew somewhat faster than NEO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NEOVCYT
RSI
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 9 days ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
87%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
78%
View a ticker or compare two or three
Ad is loading...
NEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VCYT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RSECX15.390.21
+1.38%
Russell Inv US Strategic Equity C
APHKX50.560.67
+1.34%
Artisan International Value Instl
DNDGX17.52N/A
N/A
Dunham Small Cap Growth N
LSCNX20.35N/A
N/A
Loomis Sayles Small Cap Value N
HFDTX17.99N/A
N/A
Hartford Schroders US MidCap Opps R5